Loading…
Trial terminated
| why_stopped | null | → | AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early. |
| overall_status | Active, not recruiting | → | Terminated |
Seven dimensions, unsigned magnitude 0–100. Direction is resolved separately, per entity, because one event is good for one name and bad for another.
No other named entities identified.This event has no scored competitor read-through.
No real valuation-relevant phase transition on a resolved asset for this event.This section fires only when the event carries a resolved asset and a real phase change — not guessed for every event.